Alnylam Pharmaceuticals | ALNY - Trade Creditors

Stock Price
330.17
Daily Change
-1.07 -0.32%
Monthly
-21.85%
Yearly
19.54%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $117.59M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 21.75M 1.65M Sep/2025
Agios Pharmaceuticals USD 19.55M 2.02M Sep/2025
Alnylam Pharmaceuticals USD 117.59M 15.2M Sep/2025
Amgen USD 19.64B 1.61B Sep/2025
Arrowhead Research USD 32.94M 15.26M Dec/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Incyte USD 171.92M 1.24B Sep/2025
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
Moderna USD 267M 92M Sep/2025
Neurocrine Biosciences USD 119.9M 15.3M Sep/2025
Novartis USD 4.56B 49M Sep/2025
PTC Therapeutics USD 36.62M 169.69M Sep/2025
Regeneron Pharmaceuticals USD 5.83B 4.93B Dec/2025
Sanofi EUR 22.93B 2.89B Dec/2025
Sarepta Therapeutics USD 94.02M 42.69M Sep/2025
Takeda JPY 467.59B 28.61B Dec/2025
Tectonic Therapeutic USD 1.48M 1.32M Sep/2025
Ultragenyx Pharmaceutical USD 40.57M 6.33M Sep/2025
Vertex Pharmaceuticals USD 4.03B 320.8M Sep/2025
Xencor USD 9.08M 9.45M Sep/2025